Company Directory / Biotechnology
Public · NASDAQ:PEPGFor profitBiotechnologyOxford, United Kingdom
Pepgen
PepGen is empowering nucleic acid therapeutics to go the distance.
- Founded
- 2018 8 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $240M as listed, currency not stated
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
8 years old.
Reach
Website ranked #2,192,837 in the world for traffic, about 9k visits a month.
What it does
BiotechnologyClinical TrialsMedical
Funding, as listed
$240M currency not stated
- Rounds5
- LatestPost ipo equity, Feb 2024
- Investors20, 1 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Pepgen, field by field. Contact details are held but never shown.
The company
- Name
- Pepgen
- Type
- For profit
- Status
- Public · NASDAQ:PEPG
- Founded
- 2018
- Founders
- Caroline Godfrey, Matthew Wood, Michael Gait
- Industry
- Biotechnology
- Categories
- Biotechnology, Clinical Trials, Medical
Where
- City
- Oxford
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #2,192,837
- Monthly web visits
- 9,123
Funding, as listed
- Total
- 239,675,523 (currency not stated)
- Rounds
- 5
- Latest round
- Post ipo equity
- Latest round date
- Feb 2024
- Investors
- 20
- Lead investors
- 1
- Stock listing
- NASDAQ:PEPG
- Listing status
- public
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Pepgen may be growing as it has recently achieved a significant regulatory milestone with the FDA lifting a clinical hold on its myotonic dystrophy drug, allowing the company to proceed with clinical trials. This advancement is underscored by the announcement that the first patient has been dosed in the Phase 1 FREEDOM-DM1 Clinical Trial, indicating the progression of its clinical development program. Furthermore, the company's ability to initiate this trial suggests an operational expansion and potential growth in its clinical trial activities.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.